| Bioactivity | Dacomitinib-d10 (dihydrochloride) is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1]. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| Name | Dacomitinib-d10 (dihydrochloride) |
| Formula | C24H17D10Cl3FN5O2 |
| Molar Mass | 552.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
Dacomitinib-d10 (dihydrochloride)
CAS: F: C24H17D10Cl3FN5O2 W: 552.92
Dacomitinib-d10 (dihydrochloride) is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.